Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-905-8425150
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$569.62 million
Profitability
Miscellaneous
Employees444
Next Earnings Date3/14/2019 (Estimated)
OptionableNot Optionable
Concordia International (TSE:CXR) Frequently Asked Questions
What is Concordia International's stock symbol?
Concordia International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CXR."
When is Concordia International's next earnings date?
What is the consensus analysts' recommendation for Concordia International?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concordia International in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Concordia International.
Has Concordia International been receiving favorable news coverage?
Press coverage about CXR stock has trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Concordia International earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of Concordia International's key competitors?
Some companies that are related to Concordia International include MorphoSys (MOR), Theratechnologies (TH), Resverlogix (RVX), Mesoblast (MSB), Emerald Health Therapeutics (EMH), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), 22nd Century Group (XXII), Enochian Biosciences (ENOB), IMV (IMV), Kodiak Sciences (KOD), IMV (IMV), ProMetic Life Sciences (PLI) and Monash IVF Group (MVF).
What other stocks do shareholders of Concordia International own?
Who are Concordia International's key executives?
Concordia International's management team includes the folowing people:
- Mr. Graeme Neville Duncan, CEO & Director (Age 44)
- Mr. Karl Ian Belk, Chief Operations Officer
- Mr. Adeel Ahmad, Chief Financial Officer (Age 44)
- Mr. Adam Peeler, VP of Investor Relations & Communications
- Mr. Robert Sully, Gen. Counsel
How do I buy shares of Concordia International?
Shares of CXR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How big of a company is Concordia International?
Concordia International has a market capitalization of C$0.00 and generates C$569.62 million in revenue each year. Concordia International employs 444 workers across the globe.
What is Concordia International's official website?
How can I contact Concordia International?
Concordia International's mailing address is 277 Lakeshore Rd E Suite 302, OAKVILLE, ON L6J 1H9, Canada. The company can be reached via phone at +1-905-8425150.
MarketBeat Community Rating for Concordia International (TSE CXR)
MarketBeat's community ratings are surveys of what our community members think about Concordia International and other stocks. Vote "Outperform" if you believe CXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
